Aegros on Proactive – It’s Time To Invest
Co-founder and Managing Director of Aegros, John Manusu, was interviewed recently by Proactive, a UK-based market report media outlet that covers the world’s major stock markets, to deliver the latest information regarding Aegros’ operations. There is currently a lot happening at Aegros. The world is still adjusting to the reality that global blood plasma supply […]
Meta-analysis of Clinical Trial Studies Shows the Promise of Covimmune™
A recently released academic review of 37 randomised trials examines the effectiveness of neutralising antibodies for Covid-19, and reports good news for the effectiveness of Covimmune™, Aegros’ first hyperimmune product. Reviewed by Aegros’ Medical team, an outline of this important paper is below. Source: Determinants of passive antibody effectiveness in SARS-CoV-2 infection | medRxiv Review: […]
Aegros Is Excited to Begin Covid-19 Hyperimmune Trial
Thanks to Aegros’ revolutionary HaemaFrac® technology, we have created a hyperimmune product from convalescent plasma to fight Covid-19, that is ready to begin clinical trial prior to being approved to take its place among the limited weapons doctors have to combat this pandemic virus. This is a massive step for Aegros. As a start-up company […]
The place of hyperimmunes in a Vaccine world
AEGROS AWARDED COLLABORATIVE AUSTRALIAN RESEARCH COUNCIL LINKAGE PROJECT (ARCLP) GRANT TO SUPPORT $1.8M PROJECT Hyperimmunes & Vaccines We are pleased to see the recent announcements suggesting several vaccines maybe available, hopefully, from March 2021. Hyperimmunes and vaccines work hand-in-glove. We require both of these treatment modalities to protect society from the ravages of a virus […]
